Expression of Concern: Methyldopa versus labetalol or no medication for treatment of mild and moderate chronic hypertension during pregnancy: a randomized clinical trial.Hypertens Pregnancy. 2022 Aug-Nov; 41(3-4):206.HP
Links
Pub Type(s)
Journal Article
Expression of Concern
Language
eng
PubMed ID
35916154
Citation
"Expression of Concern: Methyldopa Versus Labetalol or No Medication for Treatment of Mild and Moderate Chronic Hypertension During Pregnancy: a Randomized Clinical Trial." Hypertension in Pregnancy, vol. 41, no. 3-4, 2022, p. 206.
Expression of Concern: Methyldopa versus labetalol or no medication for treatment of mild and moderate chronic hypertension during pregnancy: a randomized clinical trial. Hypertens Pregnancy. 2022;41(3-4):206.
(2022). Expression of Concern: Methyldopa versus labetalol or no medication for treatment of mild and moderate chronic hypertension during pregnancy: a randomized clinical trial. Hypertension in Pregnancy, 41(3-4), 206. https://doi.org/10.1080/10641955.2022.2107312
Expression of Concern: Methyldopa Versus Labetalol or No Medication for Treatment of Mild and Moderate Chronic Hypertension During Pregnancy: a Randomized Clinical Trial. Hypertens Pregnancy. 2022 Aug-Nov;41(3-4):206. PubMed PMID: 35916154.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Expression of Concern: Methyldopa versus labetalol or no medication for treatment of mild and moderate chronic hypertension during pregnancy: a randomized clinical trial.
Y1 - 2022/08/02/
PY - 2022/8/3/pubmed
PY - 2022/8/3/medline
PY - 2022/8/2/entrez
SP - 206
EP - 206
JF - Hypertension in pregnancy
JO - Hypertens Pregnancy
VL - 41
IS - 3-4
SN - 1525-6065
UR - https://www.unboundmedicine.com/medline/citation/35916154/Expression_of_Concern:_Methyldopa_versus_labetalol_or_no_medication_for_treatment_of_mild_and_moderate_chronic_hypertension_during_pregnancy:_a_randomized_clinical_trial.
DB - PRIME
DP - Unbound Medicine
ER -